Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19

Summary

This study is open-label, two arms, multi-centered, phase 2b clinical trial to determine the efficacy, safety, and immunogenicity of booster vaccination (TURKOVAC) against Covid-19. The primary aim of the study is to evaluate the efficacy of a booster dose of TURKOVAC vaccine administered to subjects who have passed at least 90 days and at most 240 days after the second dose of the first course of Comirnaty (Code name: BNT162b2) vaccine.

Timeline

Start

2022-01-24

Primary completion

2023-02-25

Completion

2023-05-02

Drugs

Indications